Acquires Drug Development and Regulation (DDR), a
regulatory consultancy led by former senior officer at
European Medicines Agency (EMA)
Acquires Drug Development and Regulation (DDR), a
Global Talent Executive to Advance Company’s Commitment to a
Best-in-class Workforce
Recapitalization Will Accelerate Strategic Growth to Help Sponsors Save and Improve the Lives of Patients
Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry during the Week of Rare Disease Day 2021
Veristat Supported the NDA and Celebrates this Milestone Achievement for Children and their Families Fighting This Rare Disease
SOUTHBOROUGH, MA – 8 March 2021 –Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. This rare disease product received FDA approval on Friday, 26 February 2021, during the week when the world celebrated #RareDiseaseDay2021.
Builds on a shared pedigree of data management, statistics and programming excellence across all phases of clinical trials
Strengthening its Track Record of Successful Client Regulatory Approval Outcomes
SOUTHBOROUGH, MA – January 14, 2021 – Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)[i], and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe.
Leading the Organic and Acquisition Growth of Veristat Operations Throughout Europe
Delivering A Patient-Centric Approach to Recruitment and Retention for Clinical Trials
SOUTHBOROUGH, MA – December 7, 2020 –Veristat, a global clinical research organization, was named among the Top Patient Recruitment Companies of 2020 by Pharma Tech Outlook.
Delivering on Customer Demand for Pharmacovigilance
from Clinical Trial Conduct to Post-Marketing Support
Accelerating cell and gene therapy opportunities for patients by advancing access to knowledge and leveraging experience for sponsors to increase program success
Read More
SOUTHBOROUGH, MA – October 22, 2020 – Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.